GlassScriptPhysician profile
Mark A De Los Santos
NPI 1063901742
$3,875.75
in general payments reported to CMS, 2019-2025
20 companies · $688 in 2025
The $688 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $832 · 2022: $906 · 2023: $866 · 2024: $584 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,458.19 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $553.03 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $307.83 | 2021-2022 | |
| Abbott Laboratories | $251.71 | 2022-2025 | Mitraclip, Jot Dx, Cardiomems |
| Pfizer INC. | $171.27 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.59 | 2023-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $153.45 | 2022-2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $125.16 | 2022-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $115.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.18 | 2021-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $68.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.15 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.47 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $41.76 | 2022 | |
| Merck Sharp & Dohme LLC | $30.94 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $24.17 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $18.05 | 2023 | Inspire |
| Lexicon Pharmaceuticals, INC. | $17.64 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark De Los Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.